

Osteoporosis: risk assessment, treatment and prevention of fragility fractures Committee meeting 4

Date: 20/07/2023

Location: Virtual (Zoom)

Minutes: Final

Committee members present:		
Alison Tedstone (Chair)		(Present for notes 1 – 6)
Nicola Peel (Topic adviser)		(Present for notes 1 – 6)
Alison Ahmed		(Present for notes 1 – 6)
Irene Baker		(Present for notes 1 – 6)
Sherwin Criseno		(Present for notes 1 – 6)
Elaine Dennison		(Present for notes 1 – 6)
Karen Knapp		(Present for notes 1 – 6)
Kay Morgan		(Present for notes 1 – 6)
Rachel Muir		(Present for notes 1 – 6)
Nicholas Pipkin		(Present for notes 1 – 6)
Stuart Ralston		(Present for notes 1 – 6)
Rajesh Varma		(Present for notes 1 – 6)
Karen Whitehead		(Present for notes 1 – 6)

In attendance:		
Annette Chalker	Systematic Reviewer	(Present for notes 1 – 6)
Stephen Deed	Information Specialist	(Present for notes 1 – 6)
Sarah Glover	Information Specialist	(Present for notes 1 – 6)
Amber Hernaman	Project Manager	(Present for notes 1 – 6)
Kate Lovibond	Senior Health Economist	(Present for notes 1 – 6)
Julie Neilson	Senior Systematic Reviewer	(Present for notes 1 – 5)
Muksitur Rahman	Health Economist	(Present for notes 1 – 6)
Nick Staples	Guideline Commissioning Manager	(Present for notes 1 – 6)
Carlos Sharpin	Guideline Lead	(Present for notes 1 – 6)

Apologies:

Paul Hamilton

Committee member

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the fourth Osteoporosis guideline committee. The Committee members and attendees introduced themselves.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included.

Presentations and discussion on protocols:

- The clinical and cost effectiveness of exercise (5.3)
- Timing and duration of bisphosphonates (7.3)
- Information and support needs of adults having risk assessment (1.1)

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was the clinical and cost effectiveness strategy for monitoring fragility fracture and the clinical and cost effectiveness strategy for monitoring.

The Chair asked everyone to verbally declare any interests that had arisen since the last meeting.

3. Minutes of last meeting

Agreed.

4. Protocols

Julie Neilson led the discussions and edited the protocols on the day. The protocols were:

- The clinical and cost effectiveness of exercise (5.3)
- Timing and duration of bisphosphonates (7.3)
- Information and support needs of adults having risk assessment (1.1)

Julie Neilson discussed the QA queries for protocol:

- Treatments for preventing fragility fractures (5.1)
- Calcium and Vitamin D (5.2)

The committee were updated with the evidence on protocol:

- Accuracy of risk prediction tools (3.1)
- Risk prediction tools and bone assessment techniques (3.2)

5. Health Economics

Muksitur Rahman presented the health economics prioritisation and modelling to the committee.

6. AOB

AH informed the committee about SharePoint.

Date of next meeting: 31/08/2023

Location of next meeting: Zoom